CTRI/2012/06/002736Other1 期
A Safety, Tolerability, Pharmacokinetic, and Efficacy Study of Docetaxel InjectionConcentrate for Nano-Dispersion (DICN) in Subjects With Unresectable LocallyAdvanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
试验速览
- 阶段
- 1 期
- 状态
- Other
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Histologically or cytologically diagnosed unresectable locally advanced19 or metastatic NSCLC with taxane-based therapy a rational treatment option;
- •2.Must have been treated with at least one prior chemotherapy regimen or targeted EGFR inhibitor for locally advanced or metastatic NSCLC;
- •3.Male or female subjects with age 18 to 70 years, inclusive;
- •4.Performance status <= 2 on the ECOG performance scale;
- •5.Estimated life expectancy of at least 12-weeks;
- •6.Measurable or evaluable disease as per RECIST 1.1 criteria;
- •7.Adequate organ and immune system function as indicated by the following laboratory values, obtained <= 2 weeks prior to dosing:
- •Hematology:ANC >= 1.5 Ã? 109/L, Hemoglobin >= 9.0 g/dL, Platelets >= 100 Ã? 109/L
- •Renal:Serum creatinine <= 2.0 mg/dL
- •Hepatic:Total bilirubin <= upper limit of normal (ULN, Aspartate aminotransferase (AST) <= 1.5 Ã? ULN, Alanine aminotransferase (ALT) <= 1.5 Ã? ULN, Alkaline phosphatase <= 5 Ã? ULN
- •8.Women of child bearing potential practicing an acceptable method of birth control as judged by the investigator (such as condoms, foams,jellies, diaphragm, intrauterine device, oral or long acting injected contraceptives) from at least 2 months prior to enrollment and through the duration of the study; or postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject); with a negative serum pregnancy test;
- •9.Willing to participate and give written informed consent.
排除标准
- •1.Prior adjuvant chemotherapy or biological therapy for relapsed NSCLC if completed less than 1 year prior to first relapse of locally advanced19 or metastatic disease (prior surgery or radiotherapy allowed);
- •2.Prior docetaxel therapy for NSCLC;
- •3.Clinically significant third-space fluid collection (e.g., ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to enrollment;
- •4.Any other malignancy within 5 years with the exception of adequately treated basal or squamous cell skin cancer or adequately treated in situ carcinoma;
- •5.Known hypersensitivity to the study drugs or their excipients or analogs;
- •6.Treatment with any investigational agents within 30 days of enrollment;
- •7.Active and uncontrolled infection;
- •8.Psychiatric disorders or alcohol/chemical abuse that would interfere with consent or follow-up;
- •9.Presence of clinically symptomatic central nervous system (CNS) metastases or carcinomatous meningitis;
- •10.Pre-existing peripheral neuropathy (Grade 2 or higher â?? as per CTCAE);
- •11.Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for getting enrolled in the study;
- •12.Human immunodeficiency virus (HIV) positive or who have an Acquired Immune Deficiency Syndrome (AIDS)-related illness;
- •13.Prior radiation therapy to >= 25% of the bone marrow (e.g. whole pelvic radiation is allowed). Subjects must have recovered from the acute side effects of radiotherapy;
- •14.Prior bone marrow/stem cell transplantation;
- •15.Known Hepatitis B or C, or history of chronic active Hepatitis B or C
研究者
相似试验
尚未招募
1 期
Phase 1a study of VGA039 in healthy volunteers and patients with von Willebrand diseaseCTRI/2024/04/065934Vega Therapeutics, Inc
招募中
不适用
Safety, tolerability, efficacy and pharmacokinetic study of increasing doses of B26826 in adult patients with known or suspected intracranial lesions referred for contrast-enhanced MRI of the brain.Intracraniële laesies verwezen voor contrastverbeterde MRI van de hersenencontrast mediumintracranial lesionsNL-OMON54381Bracco Imaging S.pA.12
进行中（未招募）
1 期
Efficacy, Safety, Tolerability and Pharmacokinetics of EXN-32 and EXN-44 in patients with Parkinson¿s Disease experiencing motor fluctuationsParkinson's Desease (PD)MedDRA version: 21.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 100000004852EUCTR2017-000262-30-ITDR. REDDY’S LABORATORIES LIMITED18
进行中（未招募）
不适用
Pharmacokinetics, efficacy, tolerability and safety evaluation of the therapy with subcutaneous immunoglobulin in the treatment of hypo or agammaglobulinaemic patients. Open label phase II/III study - NDHypogammaglobulinaemia or agammaglobulinaemiaMedDRA version: 9.1Level: LLTClassification code 10060384MedDRA version: 9.1Level: LLTClassification code 10001471EUCTR2010-020167-20-ITKEDRIO
招募中
不适用
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of single and multiple escalating doses of ODM-111 and effect of food on the pharmacokinetics of ODM-111 and pharmacokinetic drug-drug interaction potential of ODM-111Chronic-/neuropathic pain10029305NL-OMON53911Orion Corporation182